CS-1002

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameCS-1002
Drug Alias NameCS-1002SHR-8068
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaHong KongMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCstone Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Suncadia Medicine Co LtdCstone PharmaceuticalsWest China Hospital Of Sichuan University +[5] 
Inactive CompaniesCstone Pharmaceutical (Shanghai) Co LtdCstone Pharmaceuticals (Suzhou) Co Ltd
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[14] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A